
|Videos|January 18, 2023
Available Systemic Therapy Options for Metastatic Castration-Resistant Prostate Cancer (mCRPC) After Docetaxel and AR-Targeted Therapy
Author(s)Stephen J. Freedland, MD
Dr Stephen J. Freedland reviews the available treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC), visceral disease, and no actionable genomic alterations, who received prior treatment with docetaxel and AR-targeted therapy.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Study shows durable 3-year outcomes with first-line gemcitabine/docetaxel in NMIBC
2
Kathryn Gessner, MD, PhD, on the challenges of selecting patients for bladder preservation
3
First-in-human bladder transplant demonstrates sustained function at 6 months
4
Experts discuss the challenge of detecting CIS in bladder cancer
5













